VRX.TO - Valeant Pharmaceuticals International, Inc.

Toronto - Toronto Delayed Price. Currency in CAD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
Currency in USD. All numbers in thousands
Revenue12/31/201712/31/201612/31/2015
Total Revenue8,724,0009,674,00010,447,000
Cost of Revenue2,548,0002,611,0002,585,000
Gross Profit6,176,0007,063,0007,862,000
Operating Expenses
Research Development361,000421,000334,000
Selling General and Administrative1,940,0002,870,0002,972,000
Non Recurring1,083,0001,665,000772,000
Others2,690,0002,673,0002,257,000
Total Operating Expenses6,074,0007,629,0006,335,000
Operating Income or Loss102,000-566,0001,527,000
Income from Continuing Operations
Total Other Income/Expenses Net-3,000-33,000-119,000
Earnings Before Interest and Taxes99,000-599,0001,408,000
Interest Expense1,840,0001,836,0001,563,000
Income Before Tax-1,741,000-2,435,000-155,000
Income Tax Expense-4,145,000-27,000133,000
Minority Interest95,000106,000119,000
Net Income From Continuing Ops2,282,000-2,409,000-312,000
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income2,404,000-2,409,000-292,000
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares2,404,000-2,409,000-292,000